ESTRO 2025 - Abstract Book

S1238

Clinical – Lower GI

ESTRO 2025

Conclusion: Our study is among the first to systematically quantify persistent vaginal and sexual dysfunction in women treated for AC, underscoring the urgent need for tailored interventions. Future research should explore dose-response relationships, the feasibility of sparing sexual organs at risk, NTCP models, and secondary prevention strategies to improve sexual health in these women.

Keywords: Anal cancer, sexual health, long-term side effect

References: 1. Jensen PT, Froeding LP. Pelvic radiotherapy and sexual function in women. Transl Androl Urol 2015; 4 (2): 186-205. 2. Wallington DG, Holliday EB. Preparing Patients for Sexual Dysfunction After Radiation for Anorectal Cancers: A Systematic Review. Practical Radiation Oncology 2021; 11 (3): 193-201.

3395

Digital Poster Anal cancer treatment in a regional cancer centre with chemoradiotherapy: Outcomes, toxicity and rates of venous thromboembolism

James Leach, Eilidh Simpson, Jennifer Morgan, Faye Robertson, Archie Macnair Edinburgh Cancer Centre, Western general Hospital, Edinburgh, United Kingdom

Purpose/Objective: Anal cancer is a rare malignancy, with increasing incidence and well-established treatment regimens. First-line radical treatment is with concurrent chemoradiation. Chemotherapy dose is stratified by age and radiotherapy is delivered as VMAT. This study aims to assess outcomes and treatment-related toxicity in patients receiving radical treatment in a regional cancer centre.